A novel Notch3-targeting antibody conjugated to a cytostatic agent, auristatin, demonstrated promising antitumor activity in preclinical models of breast cancer, NSCLC, and ovarian cancer as well as a manageable safety profile and preliminary signs of antitumor activity (PR and SD in more than 50% of enrolled patients) in advanced solid tumors in a phase 1 CT (NCT02129205) [215,216]. Here, NOTCH3 is linked to ovarian carcinoma.